Skip to content
Clinical Trials – home

Prywatna Praktyka Lekarska Anna Chudoba

Research site

Poland ul. M. Kopernika 31, 96-300 Zyrardow, Poland

  • 2 trials recruiting
  • Cardiac failure · Obesity · Type 2 diabetes mellitus
  • Adult patients

About Specializations

Prywatna Praktyka Lekarska Anna Chudoba in Zyrardow, Poland specialises in clinical trials of conditions such as Cardiac failure, Obesity, Type 2 diabetes mellitus, Cardiovascular disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The research at Prywatna Praktyka Lekarska Anna Chudoba focuses on heart failure with preserved or mildly reduced ejection fraction, aiming to improve symptoms and physical function.

  • Evaluation of anti‑inflammatory therapy in heart failure
  • Assessment of major adverse cardiovascular event outcomes
  • Investigation of novel agents for HFpEF/HFmrEF

These studies seek to test new treatments that could reduce hospitalizations and improve quality of life for patients with cardiovascular disease.

Nutritional and Metabolic Diseases

Clinical investigations address the link between obesity, systemic inflammation, and heart failure, exploring how metabolic health influences cardiovascular risk.

  • Impact of weight management on heart failure outcomes
  • Role of metabolic inflammation in cardiovascular health
  • Testing therapies targeting obesity and systemic inflammation

The work supports the development of integrated approaches that combine metabolic control with standard heart failure care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul. M. Kopernika 3196-300 ZyrardowPoland
Recruiting now
2 trials
Conditions studied
5

More sites in ZyrardowPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

5 clinical trials

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.